Sanofi: Rilzabrutinib Designated as a Breakthrough Therapy in the United States
The FDA has granted rilzabrutinib (Wayrilz) a breakthrough therapy designation for warm antibody autoimmune hemolytic anemia, while Japan has granted it orphan drug status for the same condition. These recognitions are based on ongoing clinical data evaluation.
FDA and Japanese Health Ministry Recognitions
The FDA has granted a breakthrough therapy designation to rilzabrutinib, an oral and reversible Bruton's tyrosine kinase (BTK) inhibitor, for the treatment of patients with warm antibody autoimmune hemolytic anemia (wAIHA), a rare autoimmune disease characterized by the destruction of red blood cells. Concurrently, the Japanese Ministry of Health, Labour and Welfare has awarded rilzabrutinib an orphan drug designation for the same condition. Both designations are based on the clinical data from the ongoing Phase 2b LUMINA 2 study, which assesses the efficacy and safety of rilzabrutinib in patients with wAIHA. A new Phase 3 study, LUMINA 3, is currently comparing rilzabrutinib to placebo in this patient population.
Rilzabrutinib's Broader Applications and Approvals
Rilzabrutinib is already approved in the United States, the European Union, and the United Arab Emirates under the brand name Wayrilz for the treatment of immune thrombocytopenia (ITP) and is currently under regulatory review in Japan for this indication. Beyond the approved indications for ITP, rilzabrutinib is also being studied for other rare diseases, including IgG4-related disease (IgG4-RD) and sickle cell disease (SCD). The drug has previously obtained orphan drug designation from the FDA and the EU for several conditions, as well as a fast track designation from the FDA for ITP and IgG4-RD.
